ROCKVILLE, MD – September 28, 2023 – MediWound Ltd., an Israeli biopharmaceutical company, announced the US commercial availability of NexoBrid® in adults with severe thermal burns – a first step in the product becoming the new standard of care for eschar removal. MediWound has partnered with DP Clinical, a full-service CRO located in Rockville, Maryland, since 2014 to conduct its US adult studies for this product.  “The commercialization of NexoBrid® in the US provides a treatment that can reduce the need for surgical excision and subsequent skin grafting, reduces inflammation and burn progression, and mitigates infections – all critical to the recovery of patients with deep partial and/or full-thickness thermal burns,” stated Devinder Poonian, DP Clinical’s CEO. “We are proud of our part in this product’s development and are confident NexoBrid® will have a significant positive impact on the way severe burns are treated.” Ms. Poonian continued.